Morris Gabriel S's Form 4 filing
Immix Biopharma, Inc. (IMMX) · filed Dec 10, 2025
- Accession no.
- 0001493152-25-027107
- Filed
- Dec 10, 2025
- Trade date
- Dec 8-10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $5.07K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morris Gabriel SCIK 0001889967 | Director, Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Common Stock | XIn-the-money exerciseAcquired | +156,000 | $0.80 | +$124,800 | 426,844 | Indirect | |
| Dec 10, 2025 | Common Stock | PPurchaseAcquired | +770 | $6.58 | +$5,066.6 | 291,429 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Common stock | XIn-the-money exerciseDisposed | −96,000 | $0.00 | $0 | 0 | Indirect | |
| Dec 8, 2025 | Common stock | XIn-the-money exerciseDisposed | −60,000 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.